Supplementary Figures S1-S22 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study

Supplementary Figure S1. CheckPAC study design Supplementary Figure S2. Best percentage change in target lesions from baseline in evaluable patients Supplementary Figure S3. Kaplan–Meier plot of PFS and OS in SBRT/nivolumab/ipilimumab-group (A, C) and SBRT/nivolumab-group (B, D) Supplementary Figure S4. Responder 1 Supplementary Figure S5. Responder 2 Supplementary Figure S6. Responder 3 Supplementary Figure S7. Responder 4 Supplementary Figure S8. Responder 5 Supplementary Figure S9. DOR for the five patients achieving partial response after SBRT/nivolumab/ipilimumab Supplementary Figure S10. TMB in patients who achieved clinical benefit (stable disease or partial response) compared to those with no clinical benefit (PD) Supplementary Figure S11. Distribution of PD-L1 expression according to response Supplementary Figure S12. Individual changes in CD3, CD8 and CD163 Supplementary Figure S13. Distribution of CD3, CB8, and CD163 at baseline and on treatment Supplementary Figure S14. Boxplots illustrating serum concentrations of CA 19-9 (A), CRP (B), IL-6 (C), IL-8 (D), and IL-17 (E) at baseline and during treatment Supplementary Figure S15. Individual changes in serum concentrations of CA 19-9 (A), CRP (B), IL-6 (C), IL-8 (D), and IL-17 (E) Supplementary Figure S16. Correlations between the circulating biomarkers CA 19-9, CRP, IL-6, IL-8, and IL-17 at baseline and during treatment Supplementary Figure S17. Kaplan-Meier analysis of progression free survival according to baseline serum concentrations of CA 19-9 (A), CRP (B), IL-6 (C), IL-8 (D), and IL-17 (E) Supplementary Figure S18. Kaplan-Meier analysis of overall survival according to baseline serum concentrations of CA 19-9 (A), CRP (B), IL-6 (C), IL-8 (D), and IL-17 (E) Supplementary Figure S19. Kaplan-Meier analysis of overall survival according to serum concentrations 2 months after start of treatment of CA 19-9 (A), CRP (B), IL-6 (C), IL-8 (D), and IL-17 (E) Supplementary Figure S20. Kaplan-Meier analysis of overall survival according to changes in serum concentrations of CA 19-9 (A), CRP (B), IL-6 (C), IL-8 (D), and IL-17 (E) Supplementary Figure S21. Forest plot of OS and HR from the univariate Cox regression analysis Supplementary Figure S22. Forest plot with OS and HR based on multivariate Cox regression analysis